TIOMAX: A Spanish Multicenter Registry of the real–world use of the TItanium OptiMAX® biostent: TIOMAX: Registro Español Multicéntrico Del Biostent De Titanio OptiMAX® En La Vida Real. Issue 2 (30th September 2017)

• Record Type: Journal Article
• Authors: López‐Mínguez, José R.; Nogales‐Asensio, Juan M.; Romani, Sebastián; Rivero‐Crespo, Fernando; Aragón‐Extremera, Victor M.; Jiménez‐Mazuecos, Jesús M.; Carrasco, Fernando; Oteo‐Domínguez, Juan Francisco; Bosa‐Ojeda, Francisco; Gómez‐Hospital, Joan A.
• Is Part Of: Catheterization and cardiovascular interventions. Volume 92:Issue 2(2018)
• Page Start: 261
• Page End: 268
• Publication Date: 2017-09-30
• Subjects: acute coronary syndrome with ST elevation -- bioactive titanium nitride oxide stent -- cobalt‐chromium bioactive stent -- stent thrombosis; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.27326
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: To compare the safety and efficacy of the new cobalt‐chromium bioactive stent Titan Optimax ® (Hexacath, France) with its predecessor, Titan‐2 ® . Background: The TIOMAX registry includes 784 patients who underwent percutaneous coronary intervention with these stents in 21 Spanish hospitals. Methods: Analysis of all patients in the registry without exclusion criteria, candidates for revascularization (March‐2013/July‐2014). Initially 273 patients received Titan‐2 ®, and the next 511 received the Optimax ® after its launch. Results: Mean age was 65.8 ± 13.0 (78.1% men); 49.2% were STEACS patients ( n = 322), 29.8% NSTEACS, and 27.3% had stable angina or silent ischemia. Most STEACS patients (76.4% of n = 322) were treated <24 hr after developing symptoms. All‐cause death (D), cardiac death (CD), acute myocardial infarction (AMI), and stent thrombosis (ST) at 1 month were 1.1, 0.8, 0.1, and 0.5%, respectively, with no significant differences between groups. At 1 year, the death rate was 5.5% for Titan‐2 vs. 4.1% for Optimax ®, CD was 1.8% for both groups, ST 1.1 vs. 0.6%, new AMI 3.3 vs. 2.5% and target lesion revascularization (TLR) 3.7 vs. 2.9%. The primary endpoint of the composite event (CE) of D/AMI/TLR/ST occurred in 10.3% vs. 7.6% ( p = 0.211). Patients with STEACS ( N = 322: Titan‐2/Optimax: 103/209) had better outcomes for secondary events, device‐oriented failure CD/AMI/TLR (7.8% vs. 5.0%; p = 0.330), and non‐fatal CE of AMI/ST/TLR (7.8% vs. 2.7%, p = 0.039). Conclusions: The Titan Optimax retains the efficacy and safety of Titan 2. It appears to perform better in the subgroup of STEACS patients, by reducing the non‐fatal CE of AMI/ST/TLR.